BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28629896)

  • 21. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
    J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
    Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
    J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
    Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
    J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
    Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
    Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.
    Crawford J; Swanson P; Schwarzenberger P; Sandler A; Prager D; Zhang K; Freeman DJ; Johnson CW; Krishnan K; Johnson D
    J Thorac Oncol; 2013 Dec; 8(12):1510-8. PubMed ID: 24389433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
    Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
    Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
    Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
    J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study.
    Saitoh J; Saito Y; Kazumoto T; Kudo S; Yoshida D; Ichikawa A; Sakai H; Kurimoto F; Kato S; Shibuya K
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1791-6. PubMed ID: 21601375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
    Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
    Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03.
    Kim SY; Joo J; Kim TW; Hong YS; Kim JE; Hwang IG; Kim BG; Lee KW; Kim JW; Oh HS; Ahn JB; Zang DY; Kim DY; Oh JH; Baek JY
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):889-899. PubMed ID: 29976501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
    Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
    Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
    Choy H; Akerley W; Safran H; Graziano S; Chung C; Williams T; Cole B; Kennedy T
    J Clin Oncol; 1998 Oct; 16(10):3316-22. PubMed ID: 9779707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
    Tieu BH; Sanborn RE; Thomas CR
    Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.
    Das M; Donington JS; Murphy J; Kozak M; Eclov N; Whyte RI; Hoang CD; Zhou L; Le QT; Loo BW; Wakelee H
    Clin Lung Cancer; 2011 Sep; 12(5):280-5. PubMed ID: 21752720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer.
    Sakakibara-Konishi J; Oizumi S; Kinoshita I; Shinagawa N; Kikuchi J; Kato M; Inoue T; Katoh N; Onimaru R; Shirato H; Dosaka-Akita H; Nishimura M
    Lung Cancer; 2011 Nov; 74(2):248-52. PubMed ID: 21397973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
    Fournel P; Vergnenégre A; Robinet G; Léna H; Gervais R; Le Caer H; Souquet PJ; Chavaillon JM; Bozonnat MC; Daurès JP; Chouaid C; Martel-Lafay I;
    Eur J Cancer; 2016 Jan; 52():181-7. PubMed ID: 26689864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04).
    Bradley JD; Scott CB; Paris KJ; Demas WF; Machtay M; Komaki R; Movsas B; Rubin P; Sause WT
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1173-9. PubMed ID: 11955727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.